Actual Use Trial of Atorvastatin Calcium 10 mg

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1311 participants.

Also called NCT01964326

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,311 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01964326
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01964326. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2016-01-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Actual Use Trial of Atorvastatin Calcium 10 mg
Condition
Hypercholesterolemia
Intervention (Drug)
Atorvastatin calcium 10 mg
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (class: industry)

Record details

Record id
cardio:ct-nct01964326
Content hash
303ab9ecbfe2ef8af87275b5c4c9beaffab1d83b009d7d67fb6f739748fac3b7